Editas Medicine Inc Revenue Growth Rates (EDIT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Editas Medicine Inc   (NASDAQ: EDIT)
 

EDIT's Revenue Growth by Quarter and Year

Editas Medicine Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EDIT/growth
https://api.csimarket.com/api/v1/companies/EDIT/fundamentals
https://api.csimarket.com/api/v1/companies/EDIT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
EDIT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.37
2nd Quarter June 11.89
1st Quarter March 2.83
FY 25.09

EDITs Annual Revenue
Editas Medicine Inc 's Revenue in the fiscal year 2025 $ 40.52 millions
Editas Medicine Inc 's Revenue in the fiscal year 2024 $ 32.31 millions
Editas Medicine Inc 's Revenue in the fiscal year 2023 $ 78.12 millions
Editas Medicine Inc 's Revenue in the fiscal year 2022 $ 19.71 millions
Editas Medicine Inc 's Revenue in the fiscal year 2021 $ 25.54 millions




EDIT Revenue third quarter 2026 Y/Y Growth Comment
Editas Medicine Inc reported Revenue improvement of 37.47% year on year in the third quarter 2026, to $ 10.37 millions, this is lower than Editas Medicine Inc 's recent average Revenue surge of 812.82%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Revenue growth. While Editas Medicine Inc ' s Revenue rise of 37.47% ranks overall at the positon no. 128 in the third quarter 2026.


EDIT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 37.47 %
2nd Quarter June 232.12 %
1st Quarter March -39.27 %
FY   -

Financial Statements
Editas Medicine Inc 's third quarter 2026 Revenue $ 10.37 millions EDIT's Income Statement
Editas Medicine Inc 's third quarter 2025 Revenue $ 7.54 millions Quarterly EDIT's Income Statement


EDIT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -12.83 %
2nd Quarter June 320.14 %
1st Quarter March -88.56 %
FY (Year on Year)   -


Back to EDIT Growth rate Comparisons >> Back to EDIT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #41
Overall #128

Revenue Y/Y Growth Statistics
High Average Low
12604.76 % 812.82 % -99.32 %
(Sep 30 2020)   (Sep 30 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #9
Healthcare Sector #41
Overall #128
Revenue Y/Y Growth Statistics
High Average Low
12604.76 % 812.82 % -99.32 %
(Sep 30 2020)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Editas Medicine Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
50072.13 % 1589.83 % -99.34 %
(Dec 31 2024)  


EDIT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Editas Medicine Inc disclosed drop in Revenue from the second quarter by -12.83% to $ 10.37 millions, from $ 11.89 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Editas Medicine Inc 's Revenue growth quarter on quarter, overall rank is 69.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #26
Overall #69
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #26
Overall #69
Revenue Q/Q Growth Statistics
High Average Low
50072.13 % 1589.83 % -99.34 %
(Dec 31 2024)  


EDIT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Editas Medicine Inc disclosed drop in Revenue from the second quarter by -12.83% to $ 10.37 millions, from $ 11.89 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Editas Medicine Inc 's Revenue growth quarter on quarter, overall rank is 69.


Editas Medicine Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 47.01
Y / Y Revenue Growth (TTM) 20.83 %
Year on Year Revenue Growth Overall Ranking # 3601
Seqeuential Revenue Change (TTM) 21.48 %
Seq. Revenue Growth (TTM) Overall Ranking # 1675


Cumulative Revenue growth Comment
Although Editas Medicine Inc 's Annual Revenue growth year on year were below company's average 75.6% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.83% year on year, from 7.97% in Mar 31 2026.

In the Healthcare sector 488 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1225 to 3601.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 489
Overall # 3601

Revenue TTM Y/Y Growth Statistics
High Average Low
537.6 %
 75.6 %
-73.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 268
S&P 500 # 1675
Cumulative Revenue growth Comment
Although Editas Medicine Inc 's Annual Revenue growth year on year were below company's average 75.6% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.83% year on year, from 7.97% in Mar 31 2026.

In the Healthcare sector 488 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1225 to 3601.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 489
Overall # 3601

Revenue TTM Y/Y Growth Statistics
High Average Low
537.6 %
75.6 %
-73.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 268
S&P 500 # 1675




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EDIT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions


About Editas Medicine Inc Revenue Growth Rates (EDIT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Editas Medicine Inc (CIK 1650664).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001650664-26-000103
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Editas Medicine Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.